Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CMPDOTCMKTS:LGIQNYSEARCA:LMLPOTCMKTS:LPHM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPDCompuMed$3.52-10.9%$3.52$2.00▼$6.80$4.67M0.132,299 shs506 shsLGIQLogiq$0.01$0.00▼$0.04$1.03M-0.38834 shsN/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETN$3.00+5.3%$3.00$1.00▼$18.46$3.83MN/A30,370 shs40,200 shsLPHMLee Pharmaceuticals$0.00$0.01▼$0.40$3.48M669.9154,707 shs2.02 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPDCompuMed-10.89%+3.53%-8.94%-7.37%+70.87%LGIQLogiq0.00%0.00%0.00%-20.00%-69.04%LMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETN0.00%0.00%0.00%0.00%+0.33%LPHMLee Pharmaceuticals0.00%0.00%0.00%0.00%-95.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPDCompuMedN/AN/AN/AN/AN/AN/AN/AN/ALGIQLogiqN/AN/AN/AN/AN/AN/AN/AN/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/AN/AN/AN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPDCompuMed 0.00N/AN/AN/ALGIQLogiq 0.00N/AN/AN/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETN 0.00N/AN/AN/ALPHMLee Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPDCompuMed$6.22M0.75$0.61 per share5.74$2.49 per share1.41LGIQLogiqN/AN/AN/AN/AN/AN/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/AN/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPDCompuMed$30K$0.1720.71∞N/A3.13%6.43%4.53%8/12/2025 (Estimated)LGIQLogiq-$20.10MN/A0.00N/AN/AN/A-670.77%390.95%N/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/AN/A0.00∞N/AN/AN/AN/AN/ALPHMLee PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPDCompuMedN/AN/AN/AN/AN/ALGIQLogiqN/AN/AN/AN/AN/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETN$0.6421.33%N/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPDCompuMed0.182.722.55LGIQLogiqN/A0.660.66LMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/AN/AN/ALPHMLee PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPDCompuMedN/ALGIQLogiqN/ALMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/ALPHMLee PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCMPDCompuMed22.00%LGIQLogiq44.70%LMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/ALPHMLee Pharmaceuticals55.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPDCompuMed81.33 million1.03 millionNot OptionableLGIQLogiq40102.97 million56.95 millionNot OptionableLMLPUBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETNN/A1.28 millionN/ANot OptionableLPHMLee Pharmaceuticals135.16 million15.82 millionNot OptionableLGIQ, CMPD, LMLP, and LPHM HeadlinesRecent News About These CompaniesGan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific SessionsJune 21, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or ObesityMarch 10, 2025 | prnewswire.comGan & Lee Pharmaceuticals divulges new antibody-drug conjugatesDecember 25, 2024 | bioworld.comBGan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two WeeksNovember 12, 2024 | prnewswire.comObesityWeek®? 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | medindia.netMLongboard Pharmaceuticals (LBPH) Receives a Hold from Truist FinancialNovember 11, 2024 | markets.businessinsider.comObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | prnewswire.comGan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical StudiesOctober 15, 2024 | prnewswire.comAssessing Longboard Pharmaceuticals’ Acquisition: Undervalued Potential Amidst Industry InterestOctober 14, 2024 | markets.businessinsider.comFTC Files Suit Against the Three Largest Pharmacy Benefit ManagersOctober 10, 2024 | jdsupra.comMat2A inhibitors reported in Gan & Lee Pharmaceuticals patentSeptember 27, 2024 | bioworld.comBGan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)September 14, 2024 | prnewswire.comAustin Lee ResourcingAugust 21, 2024 | pmlive.comPLee Health Embraces AI to Support Patient Care, Improve Health Outcomes, and Increase EfficiencyAugust 10, 2024 | smdailyjournal.comSFranklin Regional graduate Spencer Lee soars to semi-finals in Paris Olympics 57kg FreeStyleAugust 9, 2024 | msn.comGymnastics-Lee credits doctors and team for lifting her to Paris Olympic gloryAugust 6, 2024 | reuters.comGymnastics-Lee overcomes illness, criticism to return to Olympic podiumAugust 1, 2024 | reuters.comGan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical TrialJuly 22, 2024 | prnewswire.comGan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific SessionsJune 22, 2024 | prnewswire.comGan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific SessionsJune 17, 2024 | prnewswire.comNew MarketBeat Followers Over TimeLGIQ, CMPD, LMLP, and LPHM Company DescriptionsCompuMed OTCMKTS:CMPD$3.52 -0.43 (-10.89%) As of 06/30/2025 12:30 PM EasternCompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and medical devices. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California.Logiq OTCMKTS:LGIQLogiq, Inc. provides e-commerce solutions and services in the European Union, Southeast Asia, Africa, South Korea, and North America. The company operates its DATALogiq-branded consumer data management platform by lead generation, online marketing, and multichannel reengagement strategies through its owned and operated brands. Its DATALogiq develops a proprietary data management platform and integrates with various third-party service providers to optimize the return on its marketing efforts. The company was formerly known as Weyland Tech Inc. and changed its name to Logiq, Inc. in September 2020. Logiq, Inc. was incorporated in 2004 and is headquartered in New York, New York.UBS ETRACS Monthly Pay 2xLeveraged Wells Fargo MLP Ex-Energy ETN NYSEARCA:LMLP$3.00 +0.15 (+5.26%) As of 03/24/2020The investment seeks a return linked to the monthly compounded 2x leveraged performance of Wells Fargo Master Limited Partnership Ex-Energy Index, less investor fees. The index is intended to measure the performance of all non-energy master limited partnerships ("MLPs") listed on the New York Stock Exchange ("NYSE"), NYSE MKT or NASDAQ that satisfy market capitalization and other eligibility requirements.Lee Pharmaceuticals OTCMKTS:LPHMLee Pharmaceuticals, Inc., through its subsidiary, RONN Motor Group, Inc., focuses on the design and development, manufacture, marketing, and sale of all-electric, hydrogen-fuel cell, and zero-emission new energy vehicles (NEVs) in the United States, China, and internationally. It intends to offer hydrogen fuel cell NEVs, including sports cars, sedans, SUVs, trucks, and buses. The company was founded in 2013 and is based in Scottsdale, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
